CLXPF - Cybin gives update on psychedelic molecules progress

Cybin  (CLXPF) announces that it is progressing its CYB003 and CYB004 proprietary psychedelic molecules into Investigational New Drug (“IND”)-enabling studies.The company said that it has also initiated an API manufacturing contract with a strategic pharmaceutical manufacturing partner.The pre-clinical studies of CYB003 and CYB004 candidates included API Synthesis and optimization to demonstrate that these two psychedelic molecules show significant in vivo modifications of pharmacokinetics (“PK”) consistent with “Proof of Concept.”

For further details see:

Cybin gives update on psychedelic molecules progress